The New York Times quoted senior officials on Wednesday as saying that President Trump’s administration has selected five “candidate vaccines” that are expected to prevent the new Pneumococcal pneumonia virus, and pointed out that the White House may decide which one to ultimately adopt in the coming weeks. The US Department of Health declined to respond to the report. In addition, Trump took “hydroxychloroquine” earlier to prevent new coronary pneumonia, and no side effects occurred after completing the course of treatment. Its annual medical report showed that he was in good health, but still overweight.
The newspaper said that the “last five” were developed by Moderna Inc., AstraZeneca Plc, Pfizer Inc., Johnson & Johnson and Merck & Co. So far, it is estimated that there are more than one hundred potential vaccines in the world that are being developed or tested, including vaccines developed by French pharmaceutical company Sanofi, American pharmaceutical company Novavax and Inovio. However, the report did not mention these pharmaceutical factories.
The White House of the United States released Wednesday President Trump’s annual medical report, showing that he is healthy but still overweight. After completing a two-week course of “hydroxychloroquine” to prevent new coronary pneumonia, there were no side effects. A White House spokesman said the president is still very healthy.